Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 8/20 | 0.72 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.61 |
| ▸ | DRD1 | P21728 | 5/20 | 0.61 |
| ▸ | DRD3 | P35462 | 5/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 4/20 | 0.61 |
| ▸ | HTR2C | P28335 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.61 |
| ▸ | HTR3A | P46098 | 3/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.61 |
| ▸ | HTR2B | P41595 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | HTR7 | P34969 | 3/20 | 0.61 |
| ▸ | HTR1A | P08908 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11486355 | 0.86 | HRH1 (0.62) | HRH1HRH4CHRM2ADRA2ACHRM1 | |
| SCHEMBL12909407 | 0.84 | HRH1 (1.00) | HRH1HRH4CHRM2ADRA2ACHRM1 | |
| SCHEMBL11487549 | 0.83 | HRH1 (0.58) | HRH1HRH4CHRM2ADRA2ACHRM1 | |
| SCHEMBL20979097 | 0.83 | HRH1 (0.58) | HRH1HRH4CHRM2ADRA2ACHRM1 | |
| SCHEMBL11794079 | 0.81 | SETD7 (0.64) | HRH1HRH4CHRM2ADRA2ACHRM1 | |
| SCHEMBL10846771 | 0.81 | HRH1 (0.57) | HRH1HRH4CHRM2ADRA2ACHRM1 | |
| SCHEMBL20381726 | 0.79 | HRH1 (0.54) | HRH1HRH4CHRM2ADRA2ACHRM1 | |
| SCHEMBL20978905 | 0.79 | HRH1 (0.54) | HRH1HRH4CHRM2ADRA2ACHRM1 | |
| SCHEMBL20381716 | 0.79 | HRH1 (0.54) | HRH1HRH4CHRM2ADRA2ACHRM1 | |
| SCHEMBL20978787 | 0.78 | HRH1 (0.53) | HRH1HRH4CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872025-B2 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | BRIDGE PHARMA, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872025-B2 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | BRIDGE PHARMA, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7557128-B2 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | BRIDGE PHARMA, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557128-B2 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | BRIDGE PHARMA, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090149502-A1 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | ABERG A K GUNNAR | 2009-06-11 | — | — | US | disclosed |
| US-20090149502-A1 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | ABERG A K GUNNAR | 2009-06-11 | — | — | US | disclosed |
| US-20080287498-A1 | Having antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen | ABERG A K GUNNAR | 2008-11-20 | — | — | US | disclosed |
| US-20080287498-A1 | Having antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen | ABERG A K GUNNAR | 2008-11-20 | — | — | US | disclosed |
| US-7226934-B1 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | BRIDGE PHARMA, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226934-B1 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | BRIDGE PHARMA, INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287498-A1 | Having antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen | OPRK1, HRH2, HRH1 | HRH1 3/4885HRH4 10/4885CHRM2 1169/4885 |
| US-20090149502-A1 | Optically active isomers of ketotifen and therapeutically active metabolites thereof | OPRK1, HRH1, HRH2 | HRH1 2/4885HRH4 7/4885CHRM2 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.